Patent · US Expired

Tumor rejection antigen precursor

US5843448A · kind A · utility

15Cited by

1References

9Claims

0Family size

Assignee

Ludwig Institute of Cancer Research · US

Inventors

Yao-Tseng Chen · New York, US
Elisabeth Stockert · New York, US
Yachi Chen · New York, US
Pilar Garin-Chesa · Biberach, DE
Wolfgang J. Rettig · Biberach, DE
Lloyd J. Old · New York, US

Key dates

Filing date	Nov 17, 1995
Grant date	Dec 1, 1998
Priority date	—
Expiry date	Nov 17, 2015

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K39/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.